Tranexamic Acid for Alloplastic Breast Reconstruction
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Hematoma is a common complication of alloplastic breast reconstruction. This can lead to pain
and discomfort experienced by the patient, in addition to greater use of valuable healthcare
resources. Previous studies have shown correlation between the use of tranexamic acid (TXA),
an anti-fibrinolytic, and reduced post-surgical bleeding complication events.
In this randomized control trial (RCT) assessing TXA use in alloplastic breast
reconstruction, one breast will be randomized to have TXA applied topically, while the other
will have normal saline (NS) placebo applied. The primary objective of this prospective
blinded randomized control trial study is to determine if the administration of topical TXA
in alloplastic breast reconstruction reduces the incidence of surgical site hematoma compared
to placebo within 2 weeks following surgery. The results of this study will be used to inform
the design of a larger multicentered RCT on TXA in breast surgery.